Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
Gastric Adenocarcinoma Gastric carcinoma Gastric cancer Gastroesophageal junction cancer Gastroesophageal junction carcinoma Programmed Cell Death-1 (PD1, PD-1), Programmed Death-Ligand 1 (PDL1, PD-L1) Programmed Cell Death Receptor Ligand 2 (PDL2, PD-L2) Adenocarcinoma Capecitabine Pembrolizumab Cisplatin Pembrolizumab Monotherapy (Pembro Mono)
Lead Scientist at UCSF
- Andrew Ko
Professor, Medicine. Authored (or co-authored) 114 research publications.